These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15713903)

  • 1. Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate.
    Arditti FD; Rabinkov A; Miron T; Reisner Y; Berrebi A; Wilchek M; Mirelman D
    Mol Cancer Ther; 2005 Feb; 4(2):325-31. PubMed ID: 15713903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ allicin generation using targeted alliinase delivery for inhibition of MIA PaCa-2 cells via epigenetic changes, oxidative stress and cyclin-dependent kinase inhibitor (CDKI) expression.
    Chhabria SV; Akbarsha MA; Li AP; Kharkar PS; Desai KB
    Apoptosis; 2015 Oct; 20(10):1388-409. PubMed ID: 26286853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tumor growth by a novel approach: in situ allicin generation using targeted alliinase delivery.
    Miron T; Mironchik M; Mirelman D; Wilchek M; Rabinkov A
    Mol Cancer Ther; 2003 Dec; 2(12):1295-301. PubMed ID: 14707270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
    Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
    Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-frequency and low-intensity ultrasound accelerates alliinase-catalysed synthesis of allicin in freshly crushed garlic.
    Wang J; Cao Y; Wang C; Sun B
    J Sci Food Agric; 2011 Aug; 91(10):1766-72. PubMed ID: 21480265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A spectrophotometric assay for allicin and alliinase (Alliin lyase) activity: reaction of 2-nitro-5-thiobenzoate with thiosulfinates.
    Miron T; Rabinkov A; Mirelman D; Weiner L; Wilchek M
    Anal Biochem; 1998 Dec; 265(2):317-25. PubMed ID: 9882409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
    Pickartz T; Ringel F; Wedde M; Renz H; Klein A; von Neuhoff N; Dreger P; Kreuzer KA; Schmidt CA; Srock S; Schoeler D; Schriever F
    Exp Hematol; 2001 Dec; 29(12):1410-6. PubMed ID: 11750099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
    Perz J; Topaly J; Fruehauf S; Hensel M; Ho AD
    Leuk Lymphoma; 2002 Jan; 43(1):149-51. PubMed ID: 11908720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
    Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L; Wang DS; Lehman A; Chen CS; Johnson AJ; Marcucci G; Lee RJ; Lee LJ; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2008 Dec; 112(13):5180-9. PubMed ID: 18772452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A spectrophotometric assay for allicin, alliin, and alliinase (alliin lyase) with a chromogenic thiol: reaction of 4-mercaptopyridine with thiosulfinates.
    Miron T; Shin I; Feigenblat G; Weiner L; Mirelman D; Wilchek M; Rabinkov A
    Anal Biochem; 2002 Aug; 307(1):76-83. PubMed ID: 12137782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
    Schriever F; Huhn D
    Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
    Robak T
    Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjugates of daidzein-alliinase as a targeted pro-drug enzyme system against ovarian carcinoma.
    Appel E; Rabinkov A; Neeman M; Kohen F; Mirelman D
    J Drug Target; 2011 Jun; 19(5):326-35. PubMed ID: 20678009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.
    Parikh SA; Wierda WG
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10 Suppl 1(0 1):S27-33. PubMed ID: 20529805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
    Czuczman MS; Gregory SA
    Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in B-cell chronic lymphocytic leukemia.
    Lin TS; Lucas MS; Byrd JC
    Semin Oncol; 2003 Aug; 30(4):483-92. PubMed ID: 12939717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
    Beckwith KA; Frissora FW; Stefanovski MR; Towns WH; Cheney C; Mo X; Deckert J; Croce CM; Flynn JM; Andritsos LA; Jones JA; Maddocks KJ; Lozanski G; Byrd JC; Muthusamy N
    Leukemia; 2014 Jul; 28(7):1501-10. PubMed ID: 24445867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.